Why didn't Kangenbei's stock go up?

There are two reasons why Kang Enbei did not rise.

First, up to now, there is no annual report, and the quarterly report is expected to break even. Generally speaking, if the performance is good, it will basically be ahead of schedule, at least a forecast will be made, so it is very likely that the performance will drop sharply. No one in the organization recommended this stock. So there is an 80% chance of underperforming.

Second, the state suppressed drug prices last year, and there was no main force at all, and there was no money to pay attention to it. Therefore, the main players have no chips. This time, industrial cannabis was too sudden, and both hot money and retail investors were staring at small-cap cannabis stocks. So now the main force continues to suppress the stock price and collect chips in this position. If there is no big problem in the annual report and quarterly report at the end of the month, the market outlook of this stock will double again. The stock market has risen so much, even if the performance drops, as long as it does not exceed 50%. Then, supported by the concept of marijuana, this stock will not fall too much. If the performance is good, then this unit will be launched next month, reaching 20. Unless the stock market is substantially adjusted, three months is not a big problem.

Kang is a holding subsidiary of Kang Group Co., Ltd., which is a listed pharmaceutical enterprise integrating drug research and development, production, sales and medicinal material cultivation. The company was listed on the Shanghai Stock Exchange in April 2004 with the stock code of 600572. The controlling shareholder of the company is Zhejiang Traditional Chinese Medicine Health Industry Group Co., Ltd. (a wholly-owned subsidiary of Zhejiang Guomao Group Co., Ltd.), and the actual controller is the State-owned Assets Supervision and Administration Commission of Zhejiang Provincial People's Government.

The company is registered in Lanxi and its management headquarters is located in Hangzhou, Zhejiang Province. The company has advanced and standardized pharmaceutical production bases in Hangzhou, Lanxi, Jinhua, Jiangxi, Yunnan, Inner Mongolia, Sichuan and other places, and has built Kangenbei Botanical Medicine Industrial Park, the largest modern botanical medicine manufacturing base in China, in Lanxi.

On September 22nd, 20021year, Kang announced that it planned to transfer 42% equity of Zhenshiming to two or more transferees through public listing. If the equity transfer is successful, the company will still hold 38% of the equity of Zhenshiming, which is the single largest shareholder of Zhenshiming, but there is uncertainty about the control of Zhenshiming in the future. The company is entrusting an accounting firm and an asset appraisal company to audit and evaluate all the assets of Zhenshiming Company on June 30, 20021year, and all the work is in progress.